Rumi Fujioka

TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant <i>EGFR</i> Mutations

Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi et al. · Molecular Cancer Research · 2019 · 70 citations · Full text

Phase I trial of <scp>GBS</scp>‐01 for advanced pancreatic cancer refractory to gemcitabine

Masafumi Ikeda, Akihiro Sato, Nobuo Mochizuki et al. · Cancer Science · 2016 · 55 citations · Full text

Pancreatic Cancer, Arctium Lappa L., Chemoprevention Strategy +14

Susceptibility of <i>Snark</i>‐deficient mice to azoxymethane‐induced colorectal tumorigenesis and the formation of aberrant crypt foci

Katsuya Tsuchihara, Tsutomu Ogura, Rumi Fujioka et al. · Cancer Science · 2008 · 33 citations · Full text

Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer

Rumi Fujioka, Nobuo Mochizuki, Masafumi Ikeda et al. · PLoS ONE · 2018 · 16 citations · Full text

Gemcitabine-refractory Pancreatic Cancer, Pancreatic Cancer, Arctigenin Administration +11

Provision of a voluntary exercise environment enhances running activity and prevents obesity in<i>Snark</i>-deficient mice

Noriko Ichinoseki‐Sekine, Katsuya Tsuchihara, Ikumi Kobayashi et al. · American Journal of Physiology-Endocrinology and Metabolism · 2009 · 12 citations

Physical Activity, Fitness, Aerobic Exercise +17